Exicure, Inc.

50 articles with Exicure, Inc.

• 

  BioSpace Movers and Shakers, Aug. 9

  8/9/2019

  Biopharma companies strengthen their senior leadership teams and boards of directors.

• Exicure Reports Second Quarter 2019 Financial Results and Recent Developments

  8/8/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, reported financial results for the second quarter ended June 30, 2019 and provided an update on corporate progress.

• Exicure Appoints Dr. Bali Muralidhar of Abingworth LLP and Bosun Hau of Tybourne Capital Management to its Board of Directors

  8/7/2019

  Dr. Bali Muralidhar, a partner at Abingworth LLP, and Mr. Bosun Hau, a managing director and co-head of private equity at Tybourne Capital Management, to its Board of Directors.

• Exicure Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

  8/2/2019

  Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced the closing of its previously announced underwritten public offering of 31,625,000 shares of its common stock to the public at $2.00 per share, which included the exercise in full by the underwriters of their option to purchase 4,125,000 additional shares of common stock.

• Exicure Announces Uplisting to Nasdaq Capital Market and Pricing of $55 Million Public Offering of Common Stock

  7/31/2019

  Stock will begin trading on the Nasdaq Capital Market under the symbol “XCUR” at the opening of trading on July 31, 2019, following its previously announced approval to list its common stock on the Nasdaq Capital Market.

• Exicure Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market

  7/30/2019

  Exicure, Inc. (OTCQB: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering

• Exicure Appoints Jeffrey L. Cleland and Tim Walbert to Board of Directors

  7/22/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced its appointment of Jeffrey L. Cleland, Ph.D. and Timothy P. Walbert to its Board of Directors.

• Exicure Co-Founder Chad Mirkin Wins Kabiller Prize in Nanoscience and Nanomedicine

  7/11/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, is proud to announce Co-founder Chad A. Mirkin has been awarded the $250,000 Kabiller Prize in Nanoscience and Nanomedicine for discovering and developing spherical nucleic acids (SNAs).

• Exicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System Conference call scheduled for 8:00 am ET on June 27, 2019

  6/26/2019

  Exicure, Inc., a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system.

• Exicure Announces Preclinical Data Supporting Development of SNA Technology in the Central Nervous System

  6/26/2019

  Exicure, Inc. announced data from a preclinical study evaluating the biodistribution of SNAs in the non-human primate central nervous system.

• Exicure to Present at LD Micro 9th Invitational Conference

  6/3/2019

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CFO, David Snyder, will give a company presentation on Tuesday, June 4th, 2019 at 3:40-4:00 pm MDT at the LD Micro 9th Invitational Conference.

• Exicure to Present at TIDES 2019 on Preclinical and Clinical Development of AST-008

  5/22/2019

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a presentation at TIDES: Oligonucleotide and Peptide Therapeutics, the world’s largest meeting to accelerate oligonucleotide and peptide products from early discovery to late-stage development and commercialization.

• Exicure to Present Poster at SID 2019 Annual Meeting Demonstrating Bi-Specific Gene Targeting in Dermatology

  5/9/2019

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced a poster presentation at the Society for Investigative Dermatology Meeting, May 8-11, in Chicago.

• Exicure, Inc. Reports First Quarter 2019 Financial Results and Reviews Corporate Progress

  5/8/2019

  Reported financial results for the first quarter ended March 31, 2019 and provided an update on corporate progress.

• Exicure to Present Poster at AAN 2019

  5/3/2019

  Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, announced a poster presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, Pa.

• Exicure to Present Poster at ARVO 2019

  4/30/2019

  Exicure, Inc. announced a poster presentation at ARVO 2019 Annual Meeting in Vancouver, British Columbia.

• Exicure to Present at the AACR Annual Meeting 2019

  4/1/2019

  Data presented in collaboration with Celldex show that Exicure’s technology leads to a more potent anti-tumor response when combined with Celldex’s CDX-301

• Exicure to Present at H.C. Wainwright Global Life Sciences Conference 2019

  4/1/2019

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CEO, Dr. David Giljohann, will give a company presentation on Monday, April 8, 2019 at 11:50 am GMT at the H.C. Wainwright Global Life Sciences Conference.

• Exicure to Present at Spring Investor Summit 2019

  3/26/2019

  Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid constructs, announced that its CFO, David Snyder, will give a company presentation on Tuesday, April 2, 2019 at 9:30 am ET at the Spring Investor Summit.

• Exicure, Inc. Reports Full Year 2018 Financial Results and Corporate Progress

  3/8/2019

  Completed Phase 1 clinical trials of two drugs and began public trading